Liquidia Corp. faced setbacks in 2024 due to FDA's backdated exclusivity grant to United Therapeutics, delaying YUTREPIA's launch until May 2025. YUTREPIA's superior clinical trial results and ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while the S&P 500 gained 19% since April. Brepocitinib shows promise for NIU ...

4 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany Until recently, three classes of medical therapy were available for the ...

At the beginning of the STS session, an informal audience poll suggested more prostacyclin users in the room at a 60-40 show of hands. "Cost still pretty much favors the prostacyclin," observed ...

Medically reviewed by Lindsay Cook, PharmD Pulmonary hypertension (PH) can be challenging for healthcare professionals to ...